Indication
Lung Carcinoid Tumor
2 clinical trials
2 products
Clinical trial
A Phase 2 Multi-center, Open-label, Single Arm Study of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR InhibitorsStatus: Recruiting, Estimated PCD: 2025-05-09
Product
nab-sirolimusClinical trial
Phase 1 Trial of Dosimetry Guided 212Pb-pentixather Radioligand Therapy in Patients With Atypical Lung Carcinoids and Neuroendocrine CarcinomasStatus: Not yet recruiting, Estimated PCD: 2026-06-30
Product
Lead Pentixather